Comparison between Tysabri vs Ocrevus
| Parameter | Tysabri | Ocrevus |
|---|---|---|
| Class | Integrin inhibitor | Anti-CD20 |
| Mechanism | Blocks leukocyte migration | B-cell depletion |
| Onset | Gradual | Gradual |
| Monitoring | None | None |
| Dosing | Monthly IV | 6m IV |
| Half-life | ~11 days | ~26 days |
| Reversal Agent | None | None |
| Bleeding Risk | Moderate | Moderate |
| Indications | MS | MS |
| Renal Use | Caution | Caution |
| Pregnancy Use | Avoid | Avoid |
| Drug Interactions | Moderate | Moderate |
| Adherence Sensitivity | Moderate | Moderate |
| Best Use Case | High efficacy | Persistent depletion |
| Cost | High | High |
| Monitoring Burden | Low | Low |
| Clinical Flexibility | Moderate | Moderate |
| Real-world Convenience | Moderate | Moderate |
| Overall Verdict | Strong option | Durable |
| Food Interactions | None | None |